From: CHANDOS CALDWELL [drchanx1@earthlink.net] Sent: Sunday, March 25, 2001 7:06 PM To: fdadockets@oc.fda.gov Subject: Docket 00N-1396 & Docket 00D-1598 Please do the job of monitoring the most important food products and their sources. It is vitally important! Food is our only source of nurishment and must be as pure as it can possibly be, else we do not survive in a healthy state. I not only would survive, I want to flourish! I understand that your budgetary problems may be the cause, so that the ability of the FDA to monitor food for efficacy and safety, has been mitigated, but it must be done. It must be done to favor consumers, first, not the food multinationals or any other industrial giants. It has been clear for a long time that the industry lobbyists have had their way in persuading the FDA to do its bidding. Consumers are beginning to understand this problem and are now coming to demand that that situation change. It is critical that the FDA protect the consumer. The following are suggestions that must be considered for the titled Dockets: The FDA must require mandatory pre-market comprehensive environmental review. Unlike conventional pollutants where a given amount of pollutant causes a limited amount of damage, a small number of mutant genes could have a population explosion and reproduce forever, causing unlimited and irreparable damage. The FDA must require mandatory pre-market long-term health testing. GE products could be toxic, cause allergic responses, have lower nutritional value, and compromise immune responses in consumers. The FDA must require mandatory labeling of GE products. Without mandatory labeling, neither consumers nor health professionals will know if an allergic or toxic reaction was the result of a genetically engineered food. Consumers would be deprived of the critical knowledge needed to hold food producers liable should any of these novel products be hazardous. The FDA must end its cozy relationship with the industries it purports to be regulating. People have been allowed to work for a biotech company, then work for the FDA writing the regulatory rules on that company's product, then go back to working for the company. Ninety-two percent of FDA advisory committee meetings had at least one conflict of interest. The implications for doing otherwise are dire, indeed. CFCaldwell drchanx1@earthlink.net